Patents by Inventor Katja Pekrun

Katja Pekrun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM
    Publication number: 20230304039
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.
    Type: Application
    Filed: December 6, 2022
    Publication date: September 28, 2023
    Inventors: Katja Pekrun, Mark A. Kay
  • Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
    Patent number: 11608510
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 21, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Katja Pekrun, Mark A. Kay
  • GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES
    Publication number: 20210238260
    Abstract: AAV vectors that encode a modified Factor IX (FIX) polypeptide for gene therapy for treatment of hemophilia B are provided. The modified FIX polypeptide has increased potency compared to the wild-type FIX polypeptide. The nucleic acid encoding the modified FIX polypeptide includes a portion of an intron. The AAV vectors were generated and selected to infect islet cells, but were found to effectively transduce hepatocytes upon systemic administration, and to express high levels of FIX polypeptide. Relatively low doses of the AAV vectors can be administered to achieve a therapeutic effect. The gene therapy treatment can result in normal or near normal coagulation pharmacokinetics and normal levels of FIX, or mild hemophilia B. Combining an AAV vector with improved properties for transducing hepatocytes, and modified FIX polypeptides with enhanced potency, improves transgene expression and effectively lowers the viral dose needed to achieve therapeutically relevant FIX activity levels.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 5, 2021
    Inventors: Grant E. Blouse, Katja Pekrun, Mark A. Kay
  • NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM
    Publication number: 20200024616
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 23, 2020
    Inventors: Katja Pekrun, Mark A. Kay
  • HIV-1 viral variants for improved animal models of HIV-1 pathogenesis
    Publication number: 20040101823
    Abstract: The invention relates to HIV-1 viral variants and nucleic acids and polypeptides thereof having improved replication properties for development of suitable animal models for the study of HIV-1 pathogenesis, monkey models of HIV-1 infection comprising such variants, and methods for screening for agents that inhibit or control HIV-1 infection.
    Type: Application
    Filed: December 19, 2002
    Publication date: May 27, 2004
    Applicant: Maxygen, Inc.
    Inventors: Nay Wei Soong, Katja Pekrun, Riri Shibata